Thursday, June 11, 2026
RSS

Inside BCI

Brain-Computer Interface Industry News
Industry News Research Policy Opinion Market Moves
About Directory Glossary

Market Moves

37 articles

Market Moves

Jeff Bezos puts nearly $100M into Internet Explorer creator Thomas Reardon's new brain-inspired AI startup, in a $500M round at a $2.5B valuation

Flourish, a New York neuro-AI startup founded in 2024 by Thomas Reardon (Internet Explorer architect at Microsoft in 1994 and CTRL-labs co-founder who sold the company to Meta in 2019 for between $500 million and $1 billion) and former Amazon S-team executive Rob Williams, closed a $500 million round at a $2.5 billion valuation around 4 June 2026. Jeff Bezos contributed close to $100 million after nearly doubling an initial $50 million commitment. Other investors include Lux Capital, GV (Alphabet), and Catalio Capital. The company is building Cortex AI, an architecture-layer system that uses connectomics, the cell-by-cell mapping of biological neural connections, to design AI models that target 20-50 watts of energy draw, roughly the power consumption of a laptop and an order of magnitude lower than a server-grade GPU. Flourish has no product yet.

Jun 6

Market Moves

Allen Institute launches $400M Brain Health accelerator with Bezos family and AWS, naming ALS as one of five focus diseases

The Allen Institute announced on 2 June 2026 a $400 million global research initiative called the Brain Health accelerator, targeting neurodegenerative disease at the cell and circuit level. Capital is $200 million from the Allen Institute, $100 million from the Bezos family (whose Bezos Expeditions arm backs Synchron), and $100 million combined from AWS, NIH, and ALS advocacy organisation EverythingALS. The ALS focus is the most direct adjacency to the implantable BCI cohort, which has anchored most of its early commercial work on ALS patients.

Jun 5

Market Moves

Australian brain-mapping company Omniscient closes $27.2M Series D, naming brain-computer interfaces as a target expansion market

Sydney and San Francisco-based Omniscient Neurotechnology closed a $27.2 million (AU$41.1 million) Series D funding round on 29 May 2026, co-led by OIF Ventures and the Australian National Reconstruction Fund Corporation. The capital scales the company's FDA-cleared Quicktome connectomics platform for neurosurgical planning, with the company explicitly naming brain-computer interface, stroke, and movement disorders as the next expansion indications. Omniscient is a connectomics company rather than a BCI implant company; the BCI angle is forward-looking adjacency rather than current product.

May 29

Market Moves

Tencent takes a minority stake in Hangzhou brain-chip developer Nanochap Electronics

Tencent Holdings has acquired a minority equity stake in Nanochap Electronics, a Hangzhou-based fabless semiconductor company specialising in neural interface and biosensing SoCs for brain-computer interface and medical device applications. The investment was disclosed through a 28 May 2026 business registration filing showing Shanghai Qishan Investment, a Tencent subsidiary, added as a new shareholder. Nanochap's registered capital increased to RMB 16.8853 million. Exact stake size and investment amount have not been publicly disclosed. The move follows the April 2026 StairMed funding round in which Alibaba led and Tencent joined, and signals a sustained pattern of Chinese big-tech equity participation in the country's BCI silicon supply chain.

May 29

Market Moves

ONWARD Medical posts EUR 2M Q1 revenue, advances ARC-BCI to seven implanted participants, begins Empower BP pivotal at Craig Hospital

ONWARD Medical reported Q1 2026 results on 26 May 2026 with EUR 2.0 million in revenue (EUR 1.3 million ARC-EX systems across 100+ clinics, 70 systems supplied including first home-use shipments to US VA patients), two additional ARC-BCI participants bringing the total to seven, and first participant enrolled plus first implant in the Empower BP pivotal study at Craig Hospital, Denver. The company holds EUR 53.4 million in cash before adding over EUR 40 million from the April equity raise, extending runway into Q1 2028.

May 27

Market Moves

Inspire Medical cuts 2026 guidance to $825-875M as CMS WISeR consumes the bull case

Inspire Medical Systems reported Q1 2026 revenue of $204.6 million (up 1.6% year-on-year) on 4 May 2026 and cut full-year 2026 guidance to $825-875 million from the prior $950 million-$1 billion range issued in February. The company attributed approximately $20 million of Q1 impact to CMS WISeR prior authorization and CPT code transition uncertainty. Bank of America analyst Travis Steed downgraded the stock from Neutral to Underperform.

May 26

Market Moves

Most of Europe's leading neurotechnology companies trace back to one Geneva research campus

The Friday $7.5 million seed round for Neurosoft Bioelectronics is the latest commercial output from a Lausanne-Geneva neurotechnology cluster anchored on EPFL's Neuro-X Institute at Campus Biotech Geneva. The same cluster has produced ONWARD Medical (now NASDAQ-listed brain-spine interface company), MindMaze (Lausanne-founded brain-technology unicorn), and the academic research that China's brain-spine clinical programmes are now structurally copying.

May 26

Market Moves

Medtronic to acquire SPR Therapeutics for $650 million as top-three neuromodulation incumbents consolidate the peripheral nerve stim category

Medtronic announced on 20 May 2026 its intent to acquire SPR Therapeutics, the maker of the Sprint percutaneous peripheral nerve stimulation system, for approximately $650 million in upfront cash. The deal is the second top-three neuromodulation acquisition of a PNS specialist in seven months, after Boston Scientific completed its $533 million purchase of Nalu Medical in January 2026.

May 21

Market Moves

BlueWind Medical raises $47.8 million to scale Revi as the implantable tibial neuromodulation category separates from sacral nerve stimulation

BlueWind Medical closed $47.8 million in combined equity and debt financing on 14 May 2026 to scale US commercialisation of Revi, the only FDA-cleared implantable tibial neuromodulation device for urgency urinary incontinence. The round follows three-year OASIS pivotal trial data and Medtronic's September 2025 FDA approval of its competing Altaviva tibial system.

May 20

Market Moves

MintNeuro becomes Motif Neurotech's silicon supplier as the BCI supply chain splits from vertical integration

Imperial College London spinout MintNeuro signed a multi-year commercial supply agreement on 6 May 2026 to provide its miniaturised sensing and stimulation integrated circuits to Motif Neurotech's DOT depression implant across pre-clinical, early clinical, and pivotal trial phases. The deal lands two weeks after Motif's FDA Investigational Device Exemption clearance.

May 19

Market Moves

Bioelectronic medicine reaches commercial inflection across four companies in two weeks

Spark Biomedical's CEO appointment on May 4 caps a fortnight of substantive bioelectronic-medicine milestones: SetPoint Medical's first multiple sclerosis pilot enrolment on April 30, ResMed's $340 million acquisition of Noctrix Health on the same day, and Nervonik's $52.5 million Series B on April 27. Together the four data points map onto a single maturation arc — growth-stage capital, late-stage trial expansion, commercial scaling, incumbent acquisition — and signal that the category is moving past early-clinical research into the operational layer where all four of those events run in parallel.

May 5

Market Moves

Former Harvard chemistry chair Charles Lieber leads state-funded Shenzhen BCI lab i-BRAIN

Reuters reported on April 30 that Charles Lieber, the former chair of Harvard's chemistry department convicted in December 2021 under the US China Initiative, has been appointed director of i-BRAIN, a newly established BCI institute at the Shenzhen Medical Academy of Research and Translation. The lab gives Lieber access to dedicated nanofabrication, advanced lithography, and primate research facilities at a scale unavailable to him at Harvard. The appointment lands the same week as Axoft's $55M Asian-led Series A — the capital and talent legs of the same bilateral BCI flow.

Apr 30

Market Moves

Axoft draws C.P. Group lead in $55M Series A as US BCI company runs first acute implant in Shanghai

Cambridge, Massachusetts implantable BCI company Axoft closed a $55M oversubscribed Series A on April 29, led by Thai conglomerate Charoen Pokphand's strategic arm C.P. Group Innovation with Chinese co-investors Hillhouse and Gaorong, alongside US participants Alumni Ventures and Stanford. The same announcement disclosed Axoft's first acute intraoperative test of its Fleuron polymer probe in a Shanghai patient — the first publicly confirmed clinical use of a US BCI material in China, with more Chinese trials planned this year.

Apr 29

Market Moves

Neurable launches OEM licensing programme, opening its EEG-decoder stack to consumer hardware makers

Neurable announced on April 28 that it has formally opened its consumer-EEG technology to OEM licensing, allowing third-party hardware makers to integrate the company's brain-signal-processing stack into their own products. Named integration partners include HP Inc.'s HyperX, MeSpace, iMotions, and the United States Air Force Research Laboratory. The shift recasts Neurable from a hardware company building its own consumer products into a platform layer for the broader consumer-electronics stack.

Apr 28

Market Moves

China issues guided pricing for invasive BCI procedures as provinces begin reimbursement roll-out

China's National Healthcare Security Administration has set government-guided prices of 6,000–6,600 yuan per invasive brain-computer interface implantation procedure, with Sichuan, Hubei and Zhejiang now attaching fee schedules at the provincial level — moving the country further ahead of the United States on the reimbursement layer that will decide whether BCIs scale as routine medicine.

Apr 23

Market Moves

Sabi emerges from stealth with a thought-to-text beanie and Khosla backing

California startup Sabi has exited stealth with a non-invasive EEG beanie packing up to 100,000 miniature sensors, a brain foundation model trained on 100,000 hours of neural data, and a plan to ship a consumer thought-to-text device by the end of 2026. Khosla Ventures leads.

Apr 16